Symbio Pharmaceuticals Limited ((JP:4582)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SymBio Pharmaceuticals Limited is conducting a multi-center, global, open-label Phase 1b/2 clinical study titled ‘A Multi-Center, Global, Open-Label, Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma As Well As to Evaluate the Safety and Efficacy of Intravenous Brincidofovir in Patients With Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Using The Recommended Phase 2 Dose.’ The study aims to assess the safety, tolerability, and preliminary efficacy of Brincidofovir in patients with relapsed or refractory lymphoma, including Extranodal Natural Killer/T-cell Lymphoma.
The intervention being tested is Brincidofovir, an experimental drug administered twice weekly via intravenous infusion. It is intended to determine the optimal dosage and evaluate its safety and efficacy in treating the specified conditions.
The study follows an interventional design with a sequential intervention model and no masking. Its primary purpose is treatment-focused, aiming to establish the recommended Phase 2 dose of Brincidofovir through dose escalation in Phase 1b and subsequent treatment in Phase 2.
The study began on December 24, 2024, with the last update submitted on June 12, 2025. These dates are crucial as they mark the study’s initiation and the latest information available, reflecting ongoing progress.
This clinical study update could influence SymBio Pharmaceuticals’ stock performance by potentially boosting investor confidence if the results are positive. The study’s success may also impact the competitive landscape in the oncology sector, particularly concerning treatments for relapsed or refractory lymphoma.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.